Lower EE, et al. - Researchers investigated if a reduced dose of pegfilgrastim (3 mg) reduced the frequency of bone pain without compromising efficacy. They analyzed 265 treatments from 36 breast cancer patients who received at least one 3 mg dose of pegfilgrastim, including white blood count (WBC), and absolute granulocyte counts (AGC). Bone pain was less frequently observed with a reduced dose of pegfilgrastim. Post-treatment AGC or rate of serious infection was not significantly different in association with the reduced dose.